Back to today’s briefing

Story perspectives

ARS Pharma Names CEO, Debuts Needle-Free Spray; Shares Fall 6%

7/18/2026

28 3 Full Breakdown

Summary

Story summary

On July 7 Donn Casale became CEO and board member of ARS Pharmaceuticals after Richard Lowenthal left on July 6.
ARS Pharmaceuticals launched neffy, a needle-free nasal spray that offers a cash-payment option.
A July 1 payer-formulary review produced no decisions for neffy, delaying access.
Analysts say the needle-free format could boost adoption in schools, workplaces and public venues, a factor that coincided with the stock falling 6.23% to $7.

1 of 1

Story summary

On July 7 Donn Casale became CEO and board member of ARS Pharmaceuticals after Richard Lowenthal left on July 6.
ARS Pharmaceuticals launched neffy, a needle-free nasal spray that offers a cash-payment option.
A July 1 payer-formulary review produced no decisions for neffy, delaying access.
Analysts say the needle-free format could boost adoption in schools, workplaces and public venues, a factor that coincided with the stock falling 6.23% to $7.